Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 15, Issue 2, Pages 169-181Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2011.546351
Keywords
bone metastases; osteoclast; osteoporosis; osteosarcoma; rheumatoid arthritis
Categories
Funding
- NHMRC (Australia)
Ask authors/readers for more resources
Introduction: Osteoclasts are responsible for bone resorption and underlie a number of pathological states in which osteolysis is a feature. Over recent decades our molecular understanding of osteoclast differentiation and activation has expanded significantly, and this has allowed for the development of a number of osteoclast-targeted therapies. Areas covered: This review seeks to present the underlying molecular mechanisms of osteoclast differentiation and activity as a basis for understanding our current treatment of osteoporosis and malignant tumors in bone. Osteoclast-targeted therapies are also being evaluated for the treatment of rheumatoid arthritis, osteosarcoma and giant cell tumor of bone. Expert opinion: With concurrent advances in the fields of molecular biology, pathology and advanced imaging, osteoclast-targeted therapies show great potential for treating conditions in which excess resorption of bone is a key pathological process. Targeting of osteoclast control mechanisms offers the potential of combining 'molecular imaging' with therapeutic intervention and longitudinal monitoring of disease processes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available